Andrea Gallina
Overview
Explore the profile of Andrea Gallina including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
256
Citations
4468
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Castiglioni S, Pezzoli L, Pezzani L, Lettieri A, Di Fede E, Cereda A, et al.
Orphanet J Rare Dis
. 2024 Dec;
19(1):481.
PMID: 39707491
Background: the protein phosphatase 3 catalytic subunit alpha (PPP3CA) gene encodes for the alpha isoform of the calcineurin catalytic subunit, which controls the phosphorylation status of many targets. Currently, 23...
2.
Corsini C, Robesti D, Villa L, Montorsi F, Pietropaolo A, Panthier F, et al.
Eur Urol Focus
. 2024 Nov;
PMID: 39542788
Background And Objective: The aim of our review was to comprehensively evaluate the impact of pulse modulation technology in the field of endourology, with a focus on laser lithotripsy and...
3.
Kaufmann E, Aeppli S, Arnold W, Balermpas P, Beyer J, Bieri U, et al.
World J Urol
. 2024 Sep;
42(1):527.
PMID: 39297968
Purpose: Optimal follow-up strategies following trimodal treatment for muscle invasive bladder cancer play a crucial role in detecting and managing relapse and side-effects. This article provides a comprehensive summary of...
4.
Turco F, Buttigliero C, Delcuratolo M, Gillessen S, Vogl U, Zilli T, et al.
Clin Genitourin Cancer
. 2024 Jul;
22(5):102138.
PMID: 38996529
Prostate cancer (PC) is generally a hormone-dependent tumor. Androgen deprivation therapy ( has been the standard of care in metastatic disease for more than 80 years. Subsequent studies have highlighted...
5.
Robesti D, Moschini M, Tenace N, Burgio G, Re C, Leni R, et al.
Eur Urol Focus
. 2024 Jun;
10(6):1043-1048.
PMID: 38937195
Background And Objective: Pathological features in non-muscle-invasive bladder cancer specimens are pivotal in determining correct patients' therapeutic management. Sparse data exist regarding the importance of second opinion performed by an...
6.
Robesti D, Gallina A, Montorsi F, Briganti A, Fossati N
Curr Opin Urol
. 2024 Apr;
34(4):294-299.
PMID: 38587018
Purpose Of Review: The implementation of PET with prostate-specific membrane antigen (PSMA) tracer as primary staging tool occurred recently. Since its introduction, a novel category of patients emerged, with negative...
7.
Montorsi F, Moschini M, de Angelis M, Briganti A, Gallina A, Suardi N, et al.
Eur Urol Focus
. 2024 Apr;
10(5):868.
PMID: 38582642
No abstract available.
8.
Pederzoli F, Riba M, Venegoni C, Marandino L, Bandini M, Alchera E, et al.
Eur Urol
. 2024 Jan;
85(5):417-421.
PMID: 38184414
Neoadjuvant pembrolizumab has been shown to be a valid treatment for patients affected by muscle-invasive bladder cancer (MIBC), as demonstrated in the PURE-01 clinical trial (NCT02736266). Among the tumor-extrinsic factors...
9.
Gandaglia G, Briganti A, Suardi N, Gallina A, Cucchiara V, Vizziello D, et al.
Urol Pract
. 2023 Aug;
1(2):86-91.
PMID: 37537832
Introduction: The identification of prostatic fascial layers is of paramount importance for oncologic and functional outcomes in patients with localized prostate cancer treated with robot-assisted radical prostatectomy. We evaluated the...
10.
Cignoli D, Basile G, Fallara G, Rosiello G, Belladelli F, Cei F, et al.
BJU Int
. 2023 Mar;
132(3):283-290.
PMID: 36932928
Objective: To test the hypothesis that longer warm ischaemia time (WIT) might have a marginal impact on renal functional outcomes and might, in fact, reduce haemorrhagic risk intra-operatively. Patients And...